{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:46:29Z","timestamp":1793933189894,"version":"4.8.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,6,15]]},"abstract":"<jats:p>We investigated treatment with gemtuzumab ozogamicin (GO) in 51 patients aged 65 years or older with newly diagnosed acute myeloid leukemia (AML), refectory anemia (RA) with excess of blasts in transformation, or RA with excess blasts. GO was given in doses of 9 mg\/m2 of body-surface area on days 1 and 8 or, therapeutically equivalently, on days 1 and 15, with or without interleukin 11 (IL-11; 15 \u03bcg\/kg per day on days 3 to 28), with assignment to IL-11 treatment made randomly. Complete remission (CR) rates were 2 of 26 (8%) for GO without IL-11 and 9 of 25 (36%) for GO with IL-11. Regression analyses indicated that IL-11 was independently predictive of CR but not survival. We compared GO with or without IL-11 with idarubicin plus cytosine arabinoside (IA), as previously administered, in similar patients. The CR rate with IA was 15 of 31 (48%), and survival was superior with IA compared with GO with or without IL-11 (P\u2009=\u2009.03). Besides accounting for possible covariate effects on outcome, we also accounted for possible trial effects (TEs) arising because IA and GO with or without IL-11 were not arms of a randomized trial. Bayesian posterior probabilities that GO with or without IL-11 produced longer survival than IA, after accounting for covariates and TEs, were less than 0.01 in patients with abnormal cytogenetic findings (AC) and less than 0.15 in patients with normal cytogenetic findings (NC). Regarding CR, the analogous probabilities were less than 0.02 for GO without IL-11 (all cytogenetic groups), and for GO with IL-11, less than 0.25 for AC groups and about 0.50 for NC groups. TEs 2 to 5 times the magnitude of those previously observed would be needed to conclude that survival with GO with or without IL-11 is likely longer than with IA. Thus, there is little evidence to suggest that GO with or without IL-11 should be used instead of IA in older patients with newly diagnosed AML or myelodysplastic syndrome.<\/jats:p>","DOI":"10.1182\/blood.v99.12.4343","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T21:48:18Z","timestamp":1033508898000},"page":"4343-4349","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":124,"title":["Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside"],"prefix":"10.1182","volume":"99","author":[{"given":"Elihu H.","family":"Estey","sequence":"first","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Thall","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Mei","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miloslav","family":"Beran","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry A.","family":"Pierce","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300153170500_B1","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol."},{"key":"2020021300153170500_B2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.V96.5.1670","article-title":"How I treat older patients with AML.","volume":"96","author":"Estey","year":"2000","journal-title":"Blood."},{"key":"2020021300153170500_B3","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood.V98.13.3575","article-title":"Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C\u2013based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.","volume":"98","author":"Estey","year":"2001","journal-title":"Blood."},{"key":"2020021300153170500_B4","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1563::AID-SIM873>3.0.CO;2-L","article-title":"Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.","volume":"17","author":"Thall","year":"1998","journal-title":"Stat Med."},{"key":"2020021300153170500_B5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.1996.14.1.296","article-title":"New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.","volume":"14","author":"Thall","year":"1996","journal-title":"J Clin Oncol."},{"key":"2020021300153170500_B6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimator from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2020021300153170500_B7","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration.","volume":"60","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep."},{"key":"2020021300153170500_B8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion).","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B."},{"key":"2020021300153170500_B9","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data.","author":"Therneau","year":"2000"},{"key":"2020021300153170500_B10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots.","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc."},{"key":"2020021300153170500_B11","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3121-7","volume-title":"Modern Applied Statistics with Splus.","author":"Venables","year":"1999","edition":"3rd ed."},{"key":"2020021300153170500_B12","volume-title":"A Package for Survival Analysis in S.","author":"Therneau","year":"1994"},{"key":"2020021300153170500_B13","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","article-title":"Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin \u00b1 all-trans retinoic acid \u00b1 granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.","volume":"93","author":"Estey","year":"1999","journal-title":"Blood."},{"key":"2020021300153170500_B14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1200\/JCO.1997.15.2.483","article-title":"Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.","volume":"15","author":"Estey","year":"1997","journal-title":"J Clin Oncol."},{"key":"2020021300153170500_B15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","article-title":"Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.","volume":"12","author":"Estey","year":"1994","journal-title":"J Clin Oncol."},{"key":"2020021300153170500_B16","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood.V79.9.2246.2246","article-title":"Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.","volume":"79","author":"Estey","year":"1992","journal-title":"Blood."},{"key":"2020021300153170500_B17","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","article-title":"Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.","volume":"90","author":"Estey","year":"1997","journal-title":"Blood."},{"key":"2020021300153170500_B18","doi-asserted-by":"crossref","DOI":"10.1201\/9780429258411","volume-title":"Bayesian Data Analysis.","author":"Gelman","year":"1995"},{"key":"2020021300153170500_B19","volume-title":"Bayesian Inference Using Gibbs Sampling Manual (BUGS 0.5). Cambridge","author":"Spiegelhalter","year":"1995"},{"key":"2020021300153170500_B20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer."},{"key":"2020021300153170500_B21","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V98.4.988","article-title":"Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.","volume":"98","author":"Linenberger","year":"2001","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/12\/4343\/1685333\/h81202004343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/12\/4343\/1685333\/h81202004343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T06:15:32Z","timestamp":1733811332000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/12\/4343\/105891\/Gemtuzumab-ozogamicin-with-or-without-interleukin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,15]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.12.4343","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6,15]]}}}